News and Announcements
Altive extends partnerships through Australia and Singapore
- Published December 08, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Interest in the Altive Unicorns Fund continues to gather pace, with the firm reserving up to $30m of capacity in the fund for Morgan Stanley Wealth Management Australia. The allocation will be used to help achieve exposure to Asian and American pre-IPO exposure in a multi-manager offering in 2022.
Altive has also announced a partnership with Conduit in Singapore to develop a VCC structure to provide access for Singapore and European based clients for the strategy, reserving up to $50m in the strategy for this sleeve. This arrangement includes a distribution partnership with Melbourne based Merricks Capital.
These arrangements further add to the momentum of Altive’s business, with the firm recently achieving a “Strong” rating from Foresight Analytics for the Carlyle Secured Lending Altive Access Fund.
Commenting on these recent developments, CEO Hardy Liu, say “We are delighted with the growing interest in Altive. We believe we play an important role in the investment landscape by offering wholesale investors the opportunity to invest in a range of alternative investments that have historically only been available to institutional investors.”
Altive is an alternatives investment platform based in Hong Kong, with offices in Singapore and Sydney. They have over 80 staff and over $400 million in assets under management.
About The Company
Altive is an alternative investment platform that enables high net worth individuals (HNWIs) to invest in top-tier alternative investment opportunities from around the world. We identify, source and provide access to various investment opportunities which include shares in private companies, pre-IPO opportunities and high-quality external funds that would otherwise only be available to institutional investors.
Altive is backed by the Pacific Century Group and Alibaba and has a strategic relationship with Nuveen and Carlyle. Altive has over 80 staff in offices in Hong, Singapore and Sydney. The firm has raised over $300m on behalf of investors to date.
With a large, highly experienced investment team and deep relationships with family offices, venture capital firms and partners throughout Asia we are pleased to be offering the Altive Unicorns Fund to Australian Investors for the first time.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
